Hong Kong Auto Stock News

Recent share performance and company snapshot WuXi Biologics (Cayman) (SEHK:2269) has seen mixed share performance recently, with the stock edging up about 1% over the past day but declining around 10% over the past 3 months. The company runs an end to end biologics contract research, development, and manufacturing business, serving clients across North America, Europe, the People’s Republic of China, and other regions. It reported revenue of CN¥21,790.018 million and net income of...

At the 2026 ASCO Annual Meeting, Sichuan Kelun-Biotech Biopharmaceutical reported past Phase III and Phase II data in NSCLC, including sacituzumab tirumotecan plus pembrolizumab showing longer progression-free survival than pembrolizumab alone and lunbotinib fumarate delivering high response rates in RET fusion-positive disease, alongside encouraging first-in-human results for its B7-H3 ADC SKB500. The inclusion of sacituzumab tirumotecan data in The Lancet and the acceptance of lunbotinib’s...

Everest Medicines Stock Moves After Recent Performance Metrics Everest Medicines (SEHK:1952) has drawn fresh attention as investors review recent share performance and financial metrics, with the stock down 1% over the past day and 4.6% over the past week. See our latest analysis for Everest Medicines. That 1 day and 7 day share price weakness comes on top of a 30 day share price return of down 14.8% and a year to date decline of 24.1%. The 3 year total shareholder return of about 1.7x the...

BYD (SEHK:1211) has said it will assume liability for its advanced driver-assistance system, signaling a higher level of accountability for its technology. The company has also outlined plans to introduce solid-state batteries by 2027, targeting the next generation of electric vehicle battery performance. BYD shares last closed at HK$89.7, with the stock down 32.5% over the past year and still positive over 3 and 5 years, up 10.5% and 29.5% respectively. Against that backdrop, the company...

Insiders who acquired CN¥7.35m worth of Beauty Farm Medical and Health Industry Inc.'s ( HKG:2373 ) stock at an average...

Those following along with Softcare Limited ( HKG:2698 ) will no doubt be intrigued by the recent purchase of shares by...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

We feel now is a pretty good time to analyse Ocumension Therapeutics' ( HKG:1477 ) business as it appears the company...

JiaXing Gas Group Co., Ltd. ( HKG:9908 ) stock is about to trade ex-dividend in four days. Typically, the ex-dividend...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Those following along with Geely Automobile Holdings Limited ( HKG:175 ) will no doubt be intrigued by the recent...

Vobile Group Limited ( HKG:3738 ), is not the largest company out there, but it received a lot of attention from a...

It looks like Nissin Foods Company Limited ( HKG:1475 ) is about to go ex-dividend in the next three days. Typically...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Midland...

Tingyi (Cayman Islands) Holding Corp. ( HKG:322 ) is about to trade ex-dividend in the next 4 days. The ex-dividend...

Leadership and dividend moves reshaping the picture for COSCO SHIPPING Holdings COSCO SHIPPING Holdings (SEHK:1919) has just combined a fresh round of leadership appointments with approval of its 2025 final dividend, a pairing that gives investors new information on both governance and cash returns. See our latest analysis for COSCO SHIPPING Holdings. The share price reaction has been strong around these announcements, with a 1-day share price return of 6.68% and a 7-day share price return of...

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Recent share performance and business snapshot NetEase (SEHK:9999) has drawn investor attention after recent share price moves, with the stock down 2.3% on the day and 1 day weakness extending through the past week. Over the past month the stock is up 3.8%, while performance over the past 3 months is roughly flat, showing a 0.4% decline. Year to date, the share price is down 17.7%, and the 1 year total return shows a 3% decline. Over longer periods, NetEase has delivered a 39.1% total return...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Yip's...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

It looks like Dah Sing Financial Holdings Limited ( HKG:440 ) is about to go ex-dividend in the next 4 days. The...

Miramar Hotel and Investment Company, Limited ( HKG:71 ) stock is about to trade ex-dividend in 4 days. Typically, the...

If you are wondering whether WuXi Biologics (Cayman) is attractively priced or still carrying past baggage, the key is to separate headline moves from underlying value. The stock last closed at HK$32.74, with returns of 0.6% year to date and 32.8% over the past year, even though it is still down 27.0% over three years and 73.8% over five years. Recent share price moves have come alongside ongoing attention on WuXi Biologics (Cayman)'s role in global biologics development and contract...

Shanghai Henlius Biotech (SEHK:2696) has drawn fresh attention after China’s National Medical Products Administration approved its pertuzumab biosimilar HANBEIYOU for all local reference indications, completing a China, US and EU approval set. See our latest analysis for Shanghai Henlius Biotech. Despite the HANBEIYOU catalyst and a string of recent trial starts in oncology and immunology, Shanghai Henlius Biotech’s share price has been under pressure in the near term, with the 7 day and 30...